Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
Top Page
Lexeo Therapeutics, Inc.
(NASDAQ:LXEO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$6.50
▲(1.88% Upside)
Action:ReiteratedDate:03/31/26
The score is held down primarily by weak financial performance (pre-revenue with widening losses and accelerating cash burn) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by positive corporate developments (encouraging interim clinical data, regulatory/manufacturing progress, and a strengthened cash position/runway), while valuation is not supportive given ongoing losses and no dividend.
Positive Factors
Strong cash runway and low leverage
A $246.6M cash balance after a $154M equity raise materially reduces near-term financing risk and funds pivotal trial starts and manufacturing scale work. This financial cushion supports multi-year clinical execution and milestone delivery before commercial revenues are required.
Negative Factors
Pre-revenue with widening net losses
Lexeo remains pre-commercial while losses expanded to roughly $100M in 2025. Without product revenues, operational viability hinges on successful clinical outcomes and continued financing; prolonged development timelines will worsen the earnings trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway and low leverage
A $246.6M cash balance after a $154M equity raise materially reduces near-term financing risk and funds pivotal trial starts and manufacturing scale work. This financial cushion supports multi-year clinical execution and milestone delivery before commercial revenues are required.
Read all positive factors
Lexeo Therapeutics, Inc. (LXEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$443.04M
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)―
Beta (1Y)2.08
Revenue GrowthN/A
EPS Growth4.97%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding74,087,070
10 Day Avg. Volume1,266,890
30 Day Avg. Volume1,049,622
Financial Highlights & Ratios
PEG Ratio1.34
Price to Book (P/B)21.60
Price to Sales (P/S)0.00
P/FCF Ratio-53.83
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-211.18
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$19.67Price Target Upside208.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Lexeo Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia...
How the Company Makes Money
null...
Lexeo Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| Gross Profit | -2.08M | 0.00 | 0.00 | 654.00K | 1.66M |
| EBITDA | -107.18M | -96.19M | -64.35M | -58.04M | -50.61M |
| Net Income | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
Balance Sheet | |||||
| Total Assets | 268.69M | 146.94M | 139.81M | 97.08M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 181.77M | 121.52M | 121.47M | 77.33M | 135.86M |
| Total Debt | 7.89M | 9.92M | 11.64M | 13.48M | 0.00 |
| Total Liabilities | 22.02M | 30.10M | 26.27M | 210.03M | 192.46M |
| Stockholders Equity | 246.67M | 116.84M | 113.53M | -112.95M | -55.60M |
Cash Flow | |||||
| Free Cash Flow | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M |
| Operating Cash Flow | -98.56M | -81.15M | -59.50M | -54.56M | -44.18M |
| Investing Cash Flow | -90.25M | -94.08M | -165.00K | -901.00K | -188.00K |
| Financing Cash Flow | 216.79M | 88.78M | 103.79M | 189.00K | 150.86M |
Lexeo Therapeutics, Inc. Technical Analysis
Positive
6.38
Price Trends
6.49
Negative
7.79
Negative
6.93
Negative
Market Momentum
-0.11
Negative
53.35
Neutral
77.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXEO, the sentiment is Positive. The current price of 6.38 is above the 20-day moving average (MA) of 5.89, below the 50-day MA of 6.49, and below the 200-day MA of 6.93, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 53.35 is Neutral, neither overbought nor oversold. The STOCH value of 77.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LXEO.
Lexeo Therapeutics, Inc. Risk Analysis
Lexeo Therapeutics, Inc. disclosed 79 risk factors in its most recent earnings report. Lexeo Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lexeo Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.79B | -12.77 | -67.52% | ― | -52.08% | -69.35% | |
54 Neutral | $322.76M | -11.41 | -77.62% | ― | ― | -29.73% | |
52 Neutral | $503.83M | -1.68 | -137.70% | ― | ― | -67.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $443.04M | -53.29 | -67.33% | ― | ― | 4.97% | |
49 Neutral | $392.33M | -13.08 | -38.92% | ― | ― | 80.95% | |
41 Neutral | $27.21M | -1.38 | -135.79% | ― | -53.67% | 86.75% |
* Healthcare Sector Average
LXEO
Lexeo Therapeutics, Inc.
6.67
4.12
161.57%
TVRD
Tvardi Therapeutics
3.16
-12.80
-80.20%
LRMR
Larimar Therapeutics
4.87
2.99
159.04%
CAPR
Capricor Therapeutics
34.72
24.90
253.56%
BNTC
Benitec Biopharma
13.25
-0.43
-3.14%
DMAC
Diamedica Therapeutics
6.54
3.03
86.32%
Lexeo Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances
Positive
Mar 30, 2026
Lexeo Therapeutics reported fourth-quarter and full-year 2025 results on March 30, 2026, highlighting steady advancement of its cardiac gene therapy pipeline and a strengthened balance sheet. The company ended 2025 with $246.6 million in cash, cas...
Business Operations and StrategyExecutive/Board Changes
Lexeo Therapeutics Announces Head of Research Transition
Neutral
Feb 5, 2026
On January 30, 2026, Lexeo Therapeutics, Inc. announced that it had entered into a Transition and Consulting Agreement with Dr. Adler, under which he stepped down from his role as Head of Research effective February 1, 2026, and agreed to continue...
Business Operations and StrategyExecutive/Board Changes
Lexeo Therapeutics Announces Key Executive Leadership Changes
Positive
Jan 27, 2026
On January 27, 2026, Lexeo Therapeutics, Inc. announced that its Board of Directors appointed its current Chief Technical Officer, Jose Manuel Otero, Ph.D., as Chief Operating Officer, effective January 2, 2026, with an updated annual base salary ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.